Quantum computing combined with AI could enable pharmaceutical companies to rapidly and precisely model chemical interactions, potentially ushering in a new era of drug discovery.
In the past three years, the Food and Drug Administration has approved around 50 drugs annually, including both new compounds and products similar to existing ones. Computational drug discovery seeks to increase global understanding of biological processes and evaluate new chemical structures for potential development.
This CRA Insights looks at how a substantial increase in the number and quality of novel drugs that enter the drug evaluation funnel is likely to have impact in a variety of ways – including an expansion in the number of novel drugs that come to market each year.
Drug manufacturers should assess how these valuable assets may influence stakeholders’ valuation of new medications and adjust pricing and market access strategies accordingly.
